The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN, discusses the efforts of the myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) International Working Group (IWG) to address the unmet medical needs of patients with MDS/MPN overlap syndromes by revising response criteria and developing new clinical study protocols. Dr Savona mentions the ABLN-MARRO master clinical trial (NCT04061421), with sub-studies investigating various combination therapies in these hematological malignancies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
